Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1129-1136

  Kim, Doo Jin ^a   Yi, Bo Rim ^a   Lee, Hye Rim ^a   Kim, Seung U ^b   Choi, Kyung Chul ^a  

^a Chungbuk National University   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Cytosine deaminase; Interferon ; Pancreatic cancer; Therapeutic stem cells

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; MATRIGEL; RECOMBINANT BETA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL MIGRATION; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENETICALLY ENGINEERED STEM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; STEM CELL; STEM CELL GENE THERAPY; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOSINE DEAMINASE; DERMIS; FIBROBLASTS; FLUCYTOSINE; FLUOROURACIL; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; INTERFERON-BETA; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PRODRUGS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880599560     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2564     Document Type: Article

References (33)

1. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
2. Kang NH, Yi BR, Lim SY, Hwang KA, Baek YS, Kang KS and Choi KC: Human amniotic membrane-derived epithelial stem cells display anticancer activity in BALB/c female nude mice bearing disseminated breast cancer xenografts. Int J Oncol 40: 2022-2028, 2012.
3. Yi BR, Choi KJ, Kim SU and Choi KC: Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropism (Review). Int J Oncol 41: 798-804, 2012.
4. Yi BR, Kim SU, Kim YB, Lee HJ, Cho MH and Choi KC: Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. Oncol Rep 27: 1823-1828, 2012.
5. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 62: 3603-3608, 2002.
6. Zhang JF, Wei F, Wang HP, Li HM, Qiu W, Ren PK, Chen XF and Huang Q: Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res 29: 52, 2010.
7. Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB and Choi KC: Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res 31: 2853-2861, 2011.
8. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO and Snyder EY: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846-12851, 2000.
9. Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, Phelps DA, Remack JS, Yoon KJ, Gillespie S, Kim SU, Glackin CA, Potter PM and Danks MK: Development of a tumor-selective approach to treat metastatic cancer. PLoS One 1: e23, 2006.
10. Kim SK, Kim SU, Park IH, Bang JH, Aboody KS, Wang KC, Cho BK, Kim M, Menon LG, Black PM and Carroll RS: Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 12: 5550-5556, 2006.
11. Kim KY, Kim SU, Leung PC, Jeung EB and Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci 101: 955-962, 2010.
12. Kim SU: Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 24: 159-171, 2004.
13. Kim SU, Nakagawa E, Hatori K, Nagai A, Lee MA and Bang JH: Production of immortalized human neural crest stem cells. Methods Mol Biol 198: 55-65, 2002.
14. Evoy D, Hirschowitz EA, Naama HA, Li XK, Crystal RG, Daly JM and Lieberman MD: In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 69: 226-231, 1997.
15. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ and Crystal RG: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 6: 1055-1063, 1995.
16. Kanai F, Lan KH, Shiratori Y, Tanaka T, Ohashi M, Okudaira T, Yoshida Y, Wakimoto H, Hamada H, Nakabayashi H, Tamaoki T and Omata M: In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 57: 461-465, 1997.
17. Lan KH, Kanai F, Shiratori Y, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Tanaka T, Ohashi M and Omata M: Tumor-specific gene expression in carcinoembryonic antigen - producing gastric cancer cells using adenovirus vectors. Gastroenterology 111: 1241-1251, 1996.
18. Li Z, Shanmugam N, Katayose D, Huber B, Srivastava S, Cowan K and Seth P: Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 4: 113-117, 1997.
19. Austin EA and Huber BE: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380-387, 1993.
20. Mullen CA, Kilstrup M and Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
21. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
22. Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
23. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF and Kerr DJ: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 8: 1547-1554, 2001.
24. Crystal RG, Hirschowitz E, Lieberman M, Daly J, Kazam E, Henschke C, Yankelevitz D, Kemeny N, Silverstein R, Ohwada A, Russi T, Mastrangeli A, Sanders A, Cooke J and Harvey BG: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 8: 985-1001, 1997.
25. Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, Aguilar-Cordova E and Kim JH: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976, 2002.
26. Yi BR, Hwang KA, Kang NH, Kim SU, Jeung EB, Kim HC and Choi KC: Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-β via their tumor tropism to selectively target human hepatocarcinoma cells. Cancer Gene Ther 19: 644-651, 2012.
27. Kang NH, Hwang KA, Yi BR, Lee HJ, Jeung EB, Kim SU and Choi KC: Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models. Cancer Gene Ther 19: 412-419, 2012.
28. Kim KY, Yi BR, Lee HR, Kang NH, Jeung EB, Kim SU and Choi KC: Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol 40: 1097-1104, 2012.
29. Schmidt NO, Przylecki W, Yang W, Ziu M, Teng Y, Kim SU, Black PM, Aboody KS and Carroll RS: Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 7: 623-629, 2005.
30. Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Nishiyama Y and Kikkawa F: Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? Anticancer Agents Med Chem 8: 232-239, 2008.
31. Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH, Park IH, Black PM, Carroll RS, Lee J and Kim SK: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 15: 4925-4934, 2009.
32. Yi BR, O SN, Kang NH, Hwang KA, Kim SU, Jeung EB, Kim YB, Heo GJ and Choi KC: Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. Int J Oncol 39: 833-839, 2011.
33. Saidi RF, Williams F, Ng J, Danquah G, Mittal VK, ReMine SG and Jacobs MJ: Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am J Surg 191: 358-363, 2006.